What if aging was optional?
Tech mogul Bryan Johnson is living proof that the fountain of youth might not be a myth, it’s just expensive. At 47, this Silicon Valley disruptor has hacked his biology to achieve the impossible:
- Heart of a 37-year-old
- Skin of a 28-year-old
- Lungs of an 18-year-old
His biological age? At least 5 years younger than his chronological age.
The price tag for reverse-aging? $2 million per year, a team of 30 doctors, and over 100 daily protocols.
If that sounds extreme, it’s because it is. But it’s also a sign of the times.
For the uninitiated, Bryan Johnson is a serial entrepreneur and the founder of Kernel, a neurotech company developing non-invasive brain interfaces to map human cognition. His latest pursuit, though, taps into a far more personal frontier: longevity.
Longevity is quickly becoming the latest pursuit of the ultra wealthy- a way to extend not just life, but performance. Backed by capital, elite access, and medical infrastructure, longevity has moved from a fringe concept to a full-fledged investment category.
So, for today’s newsletter, we’re exploring the world of biohacking. In this edition, we cover-
- Clinics for the 1%
- Biohacking’s hall of fame
- The investment case for living longer
- The future of longevity
- Why health is the new luxury flex
Let’s begin.
Clinics for the 1%
The idea of radically extending human life has long captured public imagination. One of the most persistent rumours is that Walt Disney arranged to have his body cryogenically frozen after death, in the hope of being revived in the future. While widely debunked, the myth stuck because it spoke to something deeper: a desire to cheat death.
That instinct hasn’t faded; it’s just taken a new shape.
Today, the pursuit of longevity isn’t limited to individual routines or supplement stacks. It’s fast becoming institutionalised through a growing network of private clinics built exclusively for those who can afford to treat health like a portfolio, proactively and with expert oversight.
Companies like Fountain Life (co-founded by Tony Robbins), Human Longevity Inc. (founded by genome pioneer Craig Venter), and Next Health in Los Angeles are at the forefront of longevity-focused healthcare. Their model, tech-enabled, personalised, and focused on prevention, is now spreading globally. Similar clinics have emerged in Dubai, Singapore, and closer home in metros like Mumbai and Delhi.
What sets these clinics apart is the depth of their medical intelligence. These clinics run full-body MRIs, biological age clocks, and whole-genome sequencing — decoding your DNA to flag future risks for conditions like cancer, Alzheimer’s, or cardiovascular disease.
What’s crucial to realise is the big shift happening from reactive to proactive care. Traditional medicine waits for something to go wrong. These protocols aim to ensure they never appear. Early signals like inflammation, insulin resistance, hormonal imbalances, and even subtle signs of vascular aging are identified and addressed long before symptoms appear.
The result is a constantly evolving health blueprint — personalised and preventative.
And none of this comes cheap. While exact prices vary, here’s what an annual longevity-focused health regimen typically involves:
Biohacking’s hall of fame
Biohacking has become a thriving industry driven by personalities who have built extensive ecosystems around their personal experiments, philosophies, and products.
Through a mix of experimentation, storytelling, and branding, they’ve reframed longevity from a medical topic into a cultural and consumer movement.
Bryan Johnson is perhaps the boldest. Through Blueprint, his anti-aging startup, Johnson offers detailed insights into his $2 million-per-year longevity protocol and sells comprehensive diagnostics, supplements, and data-driven lifestyle programs directly to consumers. With Blueprint, Johnson positions himself as both experimenter and proof-of-concept, turning his body into a living marketing campaign. His openly shared real biological data—covering biomarkers like heart function, sleep quality, and brain imaging, reinforces his brand’s credibility and attracts a data-oriented consumer base.
Dave Asprey, often called the godfather of modern biohacking, built a health ecosystem around his brand Bulletproof, best known for butter coffee. Today, it includes 50+ products ranging from supplements to sleep tech, with reported sales crossing $100 million. His books, like The Bulletproof Diet, promote a lifestyle focused on continuous health and performance optimisation.
Bringing clinical rigour is physician Peter Attia, who occupies a unique position in the biohacking ecosystem. While he doesn’t directly sell supplements or physical products, Attia monetises a subscription-based content ecosystem around his podcast, The Drive, and his bestselling book Outlive. His premium membership tiers provide deep-dive analyses, expert Q&As, and detailed longevity frameworks.
Former elite triathlete Ben Greenfield sits at the more experimental end of the biohacking world. He runs a wide-ranging business that includes supplements, coaching programs, wellness retreats, and online courses. Greenfield combines practical fitness advice with more unconventional practices like peptide therapy, extreme fasting, and even spiritual biohacking.
Collectively, these pioneers have transitioned biohacking from a quirk to a thriving market category, each building distinct yet interconnected product ecosystems rooted in the promise of longer, healthier, more productive lives.
Follow the money
The business of biohacking is attracting serious capital, flowing in from biotech, consumer health, and performance-focused venture funds betting on the future of longevity.
Longevity. Technology’s 2024 Annual Investment Report is a goldmine for anyone seriously interested in understanding the dynamics of this sector.
Over the past decade, the industry has attracted more than $56.3 billion in total funding. In 2024 alone, investment reached $8.49 billion—more than double the previous year’s figure of $3.82 billion. While the number of deals dipped slightly from 331 to 325, the capital concentration signals increasing conviction and larger cheque sizes per deal.
The most heavily funded sub-sector this year was longevity discovery platforms, drawing $2.65 billion. These are companies focused on identifying and targeting the biological mechanisms of aging—cellular repair, genetic reprogramming, senescence, and metabolic optimisation. Notable companies raising capital in this space include Altos Labs, which is developing cell rejuvenation therapies; Retro Biosciences, focused on cellular reprogramming; and Rejuvenate Bio, working on gene therapies to extend healthspan.
Two long-term trends stand out in the report’s 10-year data:
- Post-COVID acceleration: The investment spike after 2020 suggests that COVID-19 acted as a major catalyst, shifting attention toward proactive, personalised healthcare. 2021 and 2022 were record-breaking years, with over $10 billion in deals each year.
- Geographic concentration: While global participation is growing, the landscape remains U.S.-led. The United States accounts for 57% of all longevity companies. It’s followed by Europe, the UK, and Asia, reflecting capital flow and favourable regulatory support for early-stage biotech and health innovation.
This chart reveals an industry still in early innings but with clear structure, momentum, and a growing blend of therapeutic and consumer-facing plays. While the science continues to evolve, investors are already betting on the supporting infrastructure: diagnostics, data platforms, clinics, and prevention-as-a-service models.
So, where exactly is the capital flowing and why now? It comes down to four reinforcing forces shaping the longevity thesis:
- Large Total Addressable Market (TAM):
The global longevity market is projected to grow from $21.3 billion in 2024 to $63 billion by 2035, at a CAGR of 10.37%. That scale suggests longevity is moving beyond experimental science and into the realm of consumer expectation.
- Shifting consumer demand:
In India and globally, consumer behaviour around health is undergoing a shift- from reactive treatment to proactive investment. Once viewed as indulgent, these offerings are now seen as logical extensions of premium healthcare, at par with private education, insurance, and estate planning.
- Cultural tailwinds:
The definition of “aging well” is changing. Healthspan, the number of years lived in good physical and mental health, is now being prioritised over simply living longer. Among high-income individuals globally, there is a growing focus on maintaining peak cognitive and physical function well into later decades.
- Biotechnology crossover
Biotech and diagnostic platforms are shifting from disease detection to health optimisation. AI models once used to spot illness are now flagging early risks in healthy individuals. As AI becomes faster and more predictive, diagnostics are evolving into real-time feedback systems with longevity emerging as a key use case for continuous, data-driven health management.
The longevity economy isn’t a futuristic concept anymore. It’s already here- quietly shifting capital, consumer behaviour, and the very definition of health itself.
The future of longevity
The science of staying younger, longer is moving faster than ever. As clinical research deepens and billions in venture funding pour in, longevity is shifting from theory to application.
In this section, let’s look at some of the boldest predictions shaping the future based on emerging clinical research, investment trends, and early-stage innovations. While some of these forecasts may seem speculative, they’re rooted in where science and money are already moving.
- GLP-1s: From weight loss hype to longevity’s first real drug
GLP-1 drugs like Ozempic and Wegovy, originally for diabetes, are now mainstream weight loss solutions. Novo Nordisk, their maker, briefly became Europe’s most valuable company, surpassing Finland’s GDP. But the story goes deeper: GLP-1s may also reduce inflammation, improve heart and brain function, and enhance metabolic health. As next-gen versions target muscle loss and cognitive decline, these drugs are emerging as the first real-world longevity therapies.
- Big pharma is going all-in on aging
Not long ago, aging was considered too unimportant for big pharma to touch. But that’s changing quickly. In 2024, companies like Novartis and Eli Lilly signed major longevity-focused partnerships worth hundreds of millions. Now, drug giants like Merck, J&J, and Roche are actively scouting startups working on epigenetic reprogramming, inflammation, and senescence.
Aging is being reframed not as an inevitable decline, but as a treatable condition. Internally, pharma is even building dedicated longevity units, just like it did for cancer and immunology years ago.
- Wearables will evolve from fitness trackers to medical-grade aging tools
In 2025, wearables are expected to move beyond general wellness into regulated longevity care. Paired with predictive AI, these devices will begin tracking biological age in real-time, guiding personalised interventions, and informing clinical decisions. As insurers and regulators explore reimbursement models for prevention, wearables could become core to how aging is measured, managed, and monetised.
- Partial epigenetic reprogramming will enter human trials
Partial reprogramming “resets” the biological age of cells without erasing their identity, like restoring a scratched DVD without deleting its content. After years of lab success, human trials are set to begin in 2025, led by companies like Life Biosciences and Turn Bio. Early efforts will target skin and eye aging, but the long-term goal is bolder: reversing aging at the cellular level, safely and precisely. If successful, it could mark the biggest breakthrough in longevity yet.
Why health is the new luxury flex
Among the top 1%, health has become the new currency of ambition. From biomarker tracking to sleep scores and supplement protocols, longevity isn’t just about living longer — it’s a way to signal control, discipline, and access. In a world where wealth is getting harder to flaunt, optimal health is the quiet flex.
It’s also strategic.
More years in good health mean more time to create, compound, and enjoy. For entrepreneurs, investors, and professionals who play long games, that’s real alpha.
Here’s the thought process many are starting to follow:
- Preventive health investment: Covering diagnostics, biohacking clinics, continuous monitoring, and concierge medicine.
- High-quality life extension: An estimated 10–20 additional years of productive lifespan through early intervention and health optimisation.
- Wealth compounding window: Extra decades to build capital, guide ventures, and enjoy the returns of earlier risks.
In summary
Most people measure life in years. The ambitious are starting to measure it in capacity.
Not just how long you live, but how well you operate. How sharp your mind stays. How much energy do you have at 60, 70, 80?
Because time isn’t just what’s ticking on the clock. It’s what your body and brain allow you to do with it. That’s the real unlock.
Join over 300,000 wealth creators who receive our weekly finance, business, and wealth creation insights. Subscribe to the Create Wealth newsletter here – https://bit.ly/dezerv_newsletter
Disclaimer – The information provided herein is intended solely for educational purposes. In the preparation of this material Dezerv has used information developed in-house and publicly available information and other sources believed to be reliable. All trademarks, logos, and brand names mentioned are the property of their respective owners and are used for identification purposes only. The use of these names, trademarks, and logos does not imply endorsement or recommendation.